Agenus Inc. (AGEN)
| Market Cap | 692.14M |
| Revenue (ttm) | 91.41M |
| Net Income (ttm) | -173.57M |
| Shares Out | 182.67M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 2 |
| Last Price | $3.66 |
| Previous Close | $3.96 |
| Change ($) | -0.30 |
| Change (%) | -7.58% |
| Day's Open | 3.98 |
| Day's Range | 3.62 - 4.03 |
| Day's Volume | 5,364,589 |
| 52-Week Range | 1.82 - 5.95 |
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
Agenus Inc (NASDAQ: AGEN) has announced positive preliminary results from its Phase 1 trial evaluating its iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through it...
LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
Agenus to fulfill FDA feedback for six-month follow-up on late responders Agenus to fulfill FDA feedback for six-month follow-up on late responders
LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
Agenus is nearing multiple upward inflection points. iNKT therapy trial started, showing immunotherapy leadership.
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and ...
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and ...
An off-the-shelf cell therapy for COVID-19 is sending the biotech's shares higher today.
LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers ...
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2020 Results - Earnings Call Transcript
Agenus (AGEN) delivered earnings and revenue surprises of -7.69% and 5.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am
LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vac...
LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vac...
Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...
Investor optimism is increasing ahead of an oral presentation at ESMO 2020.
LEXINGTON, Mass., Aug. 26, 2020 /PRNewswire/ -- Agenus Inc.
Agenus: Serial Underperformer's Deep I-O Pipeline Approaching Key Inflection Points
Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Agenus Inc. (AGEN) CEO Garo Armen on Q2 2020 Results - Earnings Call Transcript
Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
LEXINGTON, Mass., Aug. 6, 2020 /PRNewswire/ -- Agenus Inc.
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LEXINGTON, Mass., July 29, 2020 /PRNewswire/ -- Agenus Inc.
LEXINGTON, Mass., July 28, 2020 /PRNewswire/ -- Agenus Inc.
LEXINGTON, Mass., July 21, 2020 /PRNewswire/ -- Agenus Inc.
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
With Multiple Late Stage Cancer Therapies, Agenus Inc. Offers The Best Risk/Reward Profile In Biotechnology
Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.
Is (AGEN) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Agenus.
If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.
About AGEN
Agenus, a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 2000 |
| CEO Garo Armen | Employees 328 |
| Stock Exchange NASDAQ | Ticker Symbol AGEN |
Financial Performance
In 2019, Agenus's revenue was $150.05 million, an increase of 307.92% compared to the previous year's $36.78 million. Losses were -$107.66 million, -32.58% less than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Agenus stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 118.58% from the latest price.